Humacyte Inc (HUMA) concluded trading on Wednesday at a closing price of $2.73, with 12.0 million shares of worth about $32.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.13% during that period and on July 23, 2025 the price saw a gain of about 18.70%. Currently the company’s common shares owned by public are about 155.12M shares, out of which, 125.45M shares are available for trading.
Stock saw a price change of 14.23% in past 5 days and over the past one month there was a price change of 23.53%. Year-to-date (YTD), HUMA shares are showing a performance of -63.84% which decreased to -45.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.15 but also hit the highest price of $9.79 during that period. The average intraday trading volume for Humacyte Inc shares is 3.91 million. The stock is currently trading 16.67% above its 20-day simple moving average (SMA20), while that difference is up 15.82% for SMA50 and it goes to -20.64% lower than SMA200.
Humacyte Inc (NASDAQ: HUMA) currently have 155.12M outstanding shares and institutions hold larger chunk of about 40.18% of that.
The stock has a current market capitalization of $423.47M and its 3Y-monthly beta is at 1.89. It has posted earnings per share of -$0.69 in the same period. It has Quick Ratio of 3.28 while making debt-to-equity ratio of 2.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 8.84% while standing at 8.47% over the month.
Stock’s fiscal year EPS is expected to rise by 79.88% while it is estimated to increase by 2.45% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 14, 2025 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by H.C. Wainwright stated Humacyte Inc (HUMA) stock as a Buy in their note to investors on December 20, 2024, suggesting a price target of $15 for the stock. On December 11, 2023, H.C. Wainwright Initiated their recommendations, while on August 14, 2023, Piper Sandler Upgrade their ratings for the stock with a price target of $3.50. Stock get an Overweight rating from Cantor Fitzgerald on June 22, 2023.
